AxoGen, Inc. (NASDAQ: AXGN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.68 | Insider Own | 7.25% | Shs Outstand | 53.76M | Perf Week | 11.69% |
| Market Cap | 2.47B | Forward P/E | 67.45 | EPS next Y | 0.68 | Insider Trans | -1.11% | Shs Float | 52.20M | Perf Month | -0.02% |
| Enterprise Value | 2.40B | PEG | - | EPS next Q | 0.15 | Inst Own | - | Short Float | 10.43% | Perf Quarter | 7.81% |
| Income | -34.00M | P/S | 9.84 | EPS this Y | 164.71% | Inst Trans | - | Short Ratio | 4.30 | Perf Half Y | 31.24% |
| Sales | 251.00M | P/B | 9.65 | EPS next Y | 54.87% | ROA | -11.00% | Short Interest | 5.44M | Perf YTD | 40.42% |
| Book/sh | 4.76 | P/C | 26.01 | EPS next 5Y | 30.60% | ROE | -17.88% | 52W High | 46.95 -2.11% | Perf Year | 262.75% |
| Cash/sh | 1.77 | P/FCF | - | EPS past 3/5Y | - | ROIC | -4.65% | 52W Low | 12.39 270.94% | Perf 3Y | 440.07% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 17.41% 14.97% | Gross Margin | 74.56% | Volatility | 9.57% 5.67% | Perf 5Y | 133.30% |
| Dividend TTM | - | EV/Sales | 9.55 | EPS Y/Y TTM | -195.65% | Oper. Margin | -5.12% | ATR (14) | 2.59 | Perf 10Y | 608.17% |
| Dividend Ex-Date | Jan 27, 2010 | Quick Ratio | 5.04 | Sales Y/Y TTM | 34.22% | Profit Margin | -13.36% | RSI (14) | 66.95 | Recom | 2.16 |
| Dividend Gr. 3/5Y | - 75.54% | Current Ratio | 6.60 | EPS Q/Q | 0.00% | SMA20 | 11.99% | Beta | 1.14 | Target Price | 50.17 |
| Payout | 0.00% | Debt/Eq | 0.50 | Sales Q/Q | 22.81% | SMA50 | 9.04% | Rel Volume | 0.92 | Prev Close | 45.73 |
| Employees | 622 | LT Debt/Eq | 0.50 | Earnings | Nov 04 | SMA200 | 33.73% | Avg Volume | 1.22M | Price | 45.96 |
| IPO Date | Dec 17, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.18% 3.92% | Net Debt/EBITDA | 5.04 | Volume | 1,125,157 | Change | 0.50% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Truist Financial | $55 | |
| Jul-30-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $53 |
| Jul-29-26 | Reiterated | Jefferies | Buy | $50 → $55 |
| Apr-29-26 | Reiterated | Raymond James | Outperform | $41 → $48 |
| Apr-29-26 | Reiterated | HC Wainwright & Co. | Buy | $39 → $50 |
| Apr-29-26 | Reiterated | Canaccord Genuity | Buy | $45 → $50 |
| Apr-24-26 | Reiterated | Canaccord Genuity | Buy | $40 → $45 |
| Feb-23-26 | Reiterated | Raymond James | Outperform | $36 → $41 |
| Feb-19-26 | Initiated | Wells Fargo | Overweight | $40 |
| Dec-05-25 | Reiterated | Canaccord Genuity | Buy | $27 → $37 |
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 251 | 225 | 187 | 159 | 139 | 127 | 112 | 107 | 84 | |
| Cost of Goods Sold Incl. D&A | 63 | 58 | 45 | 37 | 30 | 23 | 22 | 17 | 13 | |
| Gross Profit | 187 | 167 | 142 | 122 | 109 | 104 | 91 | 89 | 71 | |
| Selling, General and Administrative Excl. Other | 165 | 142 | 117 | 116 | 113 | 106 | 96 | 103 | 80 | |
| Research and Development | 37 | 33 | 28 | 27 | 26 | 24 | 18 | 18 | 12 | |
| Other Operating Expense | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -13 | -8 | -3 | -21 | -30 | -25 | -23 | -31 | -20 | |
| Interest Expense | 13 | 8 | 8 | 3 | 1 | 1 | 1 | 0 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -8 | 0 | 2 | 3 | 1 | 0 | 0 | 2 | -1 | |
| Net Income Before Taxes | -34 | -16 | -10 | -22 | -29 | -27 | -24 | -29 | -22 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -34 | -16 | -10 | -22 | -29 | -27 | -24 | -29 | -22 | |
| Net Income From Continuing Operations | -34 | -16 | -10 | -22 | -29 | -27 | -24 | -29 | -22 | |
| Net Income | -34 | -16 | -10 | -22 | -29 | -27 | -24 | -29 | -22 | |
| EPS (Recurring) | -0.67 | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 | -0.60 | -0.74 | -0.60 | |
| EPS (Basic, Before Extraordinaries) | -0.67 | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 | -0.60 | -0.74 | -0.60 | |
| EPS (Diluted) | -0.68 | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 | -0.60 | -0.74 | -0.60 | |
| EBITDA | -14 | 0 | 6 | -13 | -23 | -21 | -19 | -26 | -20 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.70 | 6.69 | 3.88 | 1.85 | 3.02 | 3.02 | 6.39 | 6.52 | 9.00 | |
| Gross Margin | 74.50 | 74.22 | 75.94 | 76.73 | 78.42 | 81.89 | 81.25 | 83.18 | 84.52 | |
| Operating Margin | -5.18 | -3.56 | -1.60 | -13.21 | -21.58 | -19.69 | -20.54 | -28.97 | -23.81 | |
| Net Margin | -13.55 | -7.11 | -5.35 | -13.84 | -20.86 | -21.26 | -21.43 | -27.10 | -26.19 | |
| Shares Outstanding | 53 | 46 | 44 | 43 | 42 | 41 | 40 | 39 | 37 | |
| Market Capitalization | 2,436 | 1,506 | 725 | 294 | 419 | 384 | 716 | 698 | 756 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TYNDALL JOSEPH A. | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 14,150 | Jun 23 |
| JOHNSON JOHN | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 14,150 | Jun 23 |
| Burke William P. Mr. | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 14,250 | Jun 23 |
| Levine Alan M | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 50,893 | Jun 23 |
| Weiler Kathy Johnson | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 14,150 | Jun 23 |
| Wendell Amy McBride | Director | Jun 19 '26 | Option Exercise | 0.00 | 28,300 | 0 | 107,976 | Jun 23 |
| THOMAS PAUL | Director | Jun 19 '26 | Option Exercise | 0.00 | 37,734 | 0 | 32,395 | Jun 23 |
| Wendell Amy McBride | Director | May 08 '26 | Sale | 42.60 | 1,647 | 70,162 | 93,826 | May 12 |
| Wendell Amy McBride | Director | May 08 '26 | Option Exercise | 14.85 | 1,647 | 24,458 | 95,473 | May 12 |
| Weiler Kathy Johnson | Director | May 07 '26 | Sale | 44.09 | 16,344 | 720,623 | 0 | May 08 |
| Quackenbush Doris | Sales VP | May 07 '26 | Sale | 43.51 | 3,878 | 168,720 | 92,416 | May 08 |
| Hartley Lindsey Marie | CFO | May 07 '26 | Sale | 43.67 | 1,051 | 45,897 | 62,756 | May 08 |
| Hartley Lindsey Marie | CFO | May 07 '26 | Option Exercise | 8.24 | 5,463 | 45,004 | 65,719 | May 08 |
| JOHNSON JOHN | Director | May 07 '26 | Option Exercise | 7.04 | 11,050 | 77,792 | 11,050 | May 08 |
| JOHNSON JOHN | Director | May 07 '26 | Sale | 43.26 | 11,050 | 477,968 | 0 | May 08 |